Thursday, November 19, 2026 Vol. I · No. 7
Health · Via STAT

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

Image: STAT

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.

Read the full story at STAT ↗

statnews.com

More from the Health desk